AJP - Heart Add DOIs to your references at manuscript stage!
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol (January 4, 2008). doi:10.1152/ajpheart.00305.2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/3/H1226    most recent
00305.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sharma, U.
Right arrow Articles by Carretero, O. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sharma, U.
Right arrow Articles by Carretero, O. A
Submitted on March 12, 2007
Accepted on December 27, 2007

Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage

Umesh Sharma1, Nour-Eddine Rhaleb2, Saraswati Pokharel1, Pamela Harding3, Saman Rasoul1, Hongmei Peng1, and Oscar A Carretero1*

1 Internal Medicine, Henry Ford Hospital, Hypertension and Vascular Research, Detroit, Michigan, United States
2 Internal Medicine, Henry Ford Hospital, Hypertension and Vascular Research Division, Detroit, Michigan, United States
3 Internal Medicine, Henry Ford Hospital, Hypertension and Vascular Research, Michigan, United States

* To whom correspondence should be addressed. E-mail: oacarret1{at}hfhs.org.

Background: High blood pressure (HBP) is an important risk factor for cardiac, renal and vascular dysfunction. Excess inflammation is the major pathogenic mechanism for HBP-induced target organ damage (TOD). N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP), a tetrapeptide specifically degraded by angiotensin converting enzyme (ACE), reduces inflammation, fibrosis and TOD induced by high blood pressure. Hypothesis: Ac-SDKP exerts its anti-inflammatory effects by inhibiting: 1) differentiation of bone marrow stem cells (BMSC) to macrophages, 2) activation and migration of macrophages and 3) release of the pro-inflammatory cytokine TNF-{alpha} by activated macrophages. Methods: BMSC were freshly isolated from mouse tibias and femurs. Differentiation of murine BMSC to macrophages was analyzed by flow cytometry using F4/80 as a marker of macrophage maturation. Macrophage migration was measured in a modified Boyden chamber. TNF-{alpha} release by activated macrophages was measured by enzyme-linked immunosorbent assay (ELISA). Myocardial macrophage activation in Angiotensin-II (Ang II) treated mice was detected by Western blotting of Mac-2 (galectin-3) protein. Interstitial collagen deposition was measured by Picrosirius red staining. Results: Ac-SDKP (10 nM) reduced differentiation of cultured BMSC to mature macrophages by 24.5% [F4/80 positivity: 14.09 ± 1.06 mean fluorescent intensity (MFI) for vehicle and 10.63 ± 0.35 for Ac-SDKP; p < 0.05]. Ac-SDKP also decreased galectin-3 and macrophage colony-stimulating factor (M-CSF)-dependent macrophage migration. In addition, Ac-SDKP decreased secretion of TNF-{alpha} by macrophages stimulated with bacterial LPS. In Ang II-treated hypertensive mice, Ac-SDKP reduced expression of galectin-3, a protein produced by infiltrating macrophages in the myocardium and interstitial collagen deposition. Conclusion: This study demonstrates that part of the anti-inflammatory effect of Ac-SDKP is due to its direct effect on BMSC differentiation and macrophage activation, reinforcing the protective properties of Ac-SDKP in high blood pressure-induced inflammation and organ damage.




This article has been cited by other articles:


Home page
Ther Adv Cardiovasc DisHome page
J. A. Jessup, B. M. Westwood, M. C. Chappell, and L. Groban
Dual ACE-inhibition and AT1 receptor antagonism improves ventricular lusitropy without affecting cardiac fibrosis in the congenic mRen2.Lewis rat
Therapeutic Advances in Cardiovascular Disease, August 1, 2009; 3(4): 245 - 257.
[Abstract] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y.-H. Liu, M. D'Ambrosio, T.-d. Liao, H. Peng, N.-E. Rhaleb, U. Sharma, S. Andre, H.-J. Gabius, and O. A. Carretero
N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin
Am J Physiol Heart Circ Physiol, February 1, 2009; 296(2): H404 - H412.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C.-X. Lin, N.-E. Rhaleb, X.-P. Yang, T.-D. Liao, M. A. D'Ambrosio, and O. A. Carretero
Prevention of aortic fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in angiotensin II-induced hypertension
Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1253 - H1261.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1977 by the American Physiological Society.